US Stock MarketDetailed Quotes
VERA Vera Therapeutics
- 39.510
- -1.870-4.52%
Close Apr 30 16:00 ET
- 39.510
- 0.0000.00%
Post 17:35 ET
2.15BMarket Cap-17560P/E (TTM)
41.750High38.850Low1.09MVolume40.900Open41.380Pre Close43.11MTurnover2.72%Turnover RatioLossP/E (Static)54.45MShares50.78052wk High21.16P/B1.58BFloat Cap7.10052wk Low--Dividend TTM39.88MShs Float50.780Historical High--Div YieldTTM7.01%Amplitude5.200Historical Low39.714Avg Price1Lot Size
Vera Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -36.37%-92.18M | -18.82%-25.14M | -24.72%-22.97M | 6.63%-17.77M | -192.75%-26.29M | -185.12%-67.6M | -228.70%-21.16M | -235.89%-18.42M | -148.31%-19.03M | -117.93%-8.98M |
| Net income from continuing operations | -7.79%-95.99M | 20.91%-25.66M | 18.54%-20.1M | -35.74%-20.16M | -76.00%-30.07M | -173.10%-89.06M | -92.55%-32.44M | -224.25%-24.68M | -332.15%-14.85M | -262.43%-17.09M |
| Depreciation and amortization | -382.98%-4.09M | -95.48%-1.17M | -848.68%-1.44M | -816.04%-971K | -5,722.22%-506K | -580.68%-846K | -1,965.63%-597K | -357.63%-152K | -312.00%-106K | -74.29%9K |
| Other non cash items | -62.07%2.22M | 1.14%532K | -87.00%549K | 2.36%564K | 2.66%579K | 46.54%5.86M | -89.21%526K | 3,477.60%4.22M | 444.38%551K | 195.59%564K |
| Change In working capital | -186.99%-5.87M | -124.33%-2.08M | -956.77%-4.91M | 101.20%86K | -82.35%1.04M | 92.17%6.75M | 98.88%8.54M | -151.90%-465K | -197.11%-7.19M | 688.84%5.87M |
| -Change in prepaid assets | 102.11%173K | 267.84%809K | -1,255.19%-2.09M | 36.24%-2.3M | 195.10%3.75M | -254.81%-8.18M | -168.27%-482K | -124.37%-154K | -2.47%-3.6M | -3,003.94%-3.94M |
| -Change in payables and accrued expense | -117.50%-3.09M | -122.99%-2.24M | -640.30%-2.17M | 226.34%3.35M | -119.95%-2.03M | 200.65%17.64M | 167.36%9.72M | 52.27%402K | -341.79%-2.65M | 1,067.16%10.17M |
| -Change in other current assets | -178.38%-309K | 92.31%-1K | 93.94%-4K | 1.32%-299K | -101.85%-5K | -117.65%-111K | 74.51%-13K | ---66K | ---303K | --271K |
| -Change in other current liabilities | -1.65%-2.65M | 6.35%-649K | -0.62%-651K | -4.56%-665K | -8.63%-680K | ---2.6M | ---693K | ---647K | ---636K | ---626K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -36.37%-92.18M | -18.82%-25.14M | -24.72%-22.97M | 6.63%-17.77M | -192.75%-26.29M | -185.12%-67.6M | -228.70%-21.16M | -235.89%-18.42M | -148.31%-19.03M | -117.93%-8.98M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 44.11%-39.43M | 38.10%18.56M | 765.08%16.23M | -105.37%-86.45M | 131.01%12.23M | -1,578.21%-70.55M | 368.74%13.44M | -2.44M | -5,388.19%-42.09M | -39.46M |
| Net PPE purchase and sale | -1.61%-63K | ---63K | --0 | --0 | --0 | ---62K | --0 | ---38K | ---6K | ---18K |
| Net investment purchase and sale | 44.15%-39.37M | 38.57%18.62M | 775.60%16.23M | -105.40%-86.45M | 131.02%12.23M | ---70.49M | --13.44M | ---2.4M | ---42.09M | ---39.44M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 44.11%-39.43M | 38.10%18.56M | 765.08%16.23M | -105.37%-86.45M | 131.01%12.23M | -1,578.21%-70.55M | 368.74%13.44M | ---2.44M | -5,388.19%-42.09M | ---39.46M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 31.01%133.54M | 19.89%24.83M | -67.29%297K | 800.00%432K | 34.53%107.98M | 89.18%101.93M | 320.83%20.71M | 908K | -99.90%48K | 286,771.43%80.27M |
| Net issuance payments of debt | 24.85%24.74M | ---- | ---- | ---- | ---- | 302.68%19.82M | ---- | ---- | ---- | ---- |
| Net common stock issuance | 33.52%115M | --0 | --0 | --0 | 33.52%115M | 68.30%86.13M | ---1K | --1K | -100.00%1K | --86.13M |
| Proceeds from stock option exercised by employees | -49.30%1.06M | -89.48%87K | -69.54%297K | 819.15%432K | 2.56%240K | 278.73%2.08M | --827K | --975K | -77.40%47K | -31.58%234K |
| Net other financing activities | -19.01%-7.26M | --0 | --0 | --0 | -19.03%-7.26M | -120.51%-6.1M | --67K | ---68K | --0 | -1,552.03%-6.1M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 31.01%133.54M | 19.89%24.83M | -67.29%297K | 800.00%432K | 34.53%107.98M | 89.18%101.93M | 320.83%20.71M | --908K | -99.90%48K | 286,771.43%80.27M |
| Net cash flow | ||||||||||
| Beginning cash position | -45.29%43.75M | -10.81%27.44M | -33.18%33.89M | 23.15%137.68M | -45.29%43.75M | 48.10%79.97M | -64.42%30.77M | -44.85%50.72M | 124.28%111.8M | 48.10%79.97M |
| Current changes in cash | 105.33%1.93M | 40.48%18.24M | 67.68%-6.45M | -69.93%-103.79M | 195.07%93.93M | -239.45%-36.22M | 299.23%12.98M | -263.82%-19.95M | -245.01%-61.08M | 867.22%31.83M |
| End cash Position | 4.41%45.68M | 4.41%45.68M | -10.81%27.44M | -33.18%33.89M | 23.15%137.68M | -45.29%43.75M | -45.29%43.75M | -64.42%30.77M | -44.85%50.72M | 124.28%111.8M |
| Free cash flow | -36.34%-92.24M | -19.11%-25.21M | -24.46%-22.97M | 6.65%-17.77M | -192.17%-26.29M | -185.38%-67.66M | -228.70%-21.16M | -236.58%-18.46M | -148.39%-19.04M | -118.37%-9M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg